The renal and cardiovascular effects of natriuretic peptides

Advances in Physiology Education

Volumn 41, Issue 2, 2017, Pages 179-185

  Wong, Philip Ching Yat ^a   Guo, Jun ^a   Zhang, Aidong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOBUTYRIC ACID DERIVATIVE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ENALAPRIL; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; SACUBITRIL PLUS VALSARTAN; TETRAZOLE DERIVATIVE;

BLOOD; DISEASE COURSE; HEART FAILURE; HUMAN; KIDNEY; METABOLISM; PATHOPHYSIOLOGY;

AMINOBUTYRATES; ATRIAL NATRIURETIC FACTOR; DISEASE PROGRESSION; ENALAPRIL; HEART FAILURE; HUMANS; KIDNEY; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; NATRIURETIC PEPTIDES; TETRAZOLES;

EID: 85032668853     PISSN: 10434046     EISSN: 15221229     Source Type: Journal    
DOI: 10.1152/ADVAN.00177.2016     Document Type: Article

References (64)

1. 1. Abell TJ, Richards AM, Ikram H, Espiner EA, Yandle T. Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet-derived growth factor. Biochem Biophys Res Commun 160: 1392–1396, 1989. doi:10.1016/S0006-291X(89)80158-5.
2. 2. Almeida FA, Suzuki M, Maack T. Atrial natriuretic factor increases hematocrit and decreases plasma volume in nephrectomized rats. Life Sci 39: 1193–1199, 1986. doi:10.1016/0024-3205(86)90351-6.
3. 3. Anderson JV, Donckier J, Payne NN, Beacham J, Slater JD, Bloom SR. Atrial natriuretic peptide: evidence of action as a natriuretic hormone at physiological plasma concentrations in man. Clin Sci (Lond) 72: 305–312, 1987. doi:10.1042/cs0720305.
4. 4. Barbee RW, Trippodo NC. The contribution of atrial natriuretic factor to acute volume natriuresis in rats. Am J Physiol Renal Fluid Electrolyte Physiol 253: F1129–F1135, 1987.
5. 5. Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML. Diverse biological actions of atrial natriuretic peptide. Physiol Rev 70: 665–699, 1990.
6. 6. Calderone A, Thaik CM, Takahashi N, Chang DLF, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growthpromoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 101: 812–818, 1998. doi:10.1172/JCI119883.
7. 7. Chen W, Gassner B, Börner S, Nikolaev VO, Schlegel N, Waschke J, Steinbronn N, Strasser R, Kuhn M. Atrial natriuretic peptide enhances microvascular albumin permeability by the caveolae-mediated transcellular pathway. Cardiovasc Res 93: 141–151, 2012. doi:10.1093/cvr/cvr279.
8. 8. Costa MA, Elesgaray R, Balaszczuk AM, Arranz C. Role of NPR-C natriuretic receptor in nitric oxide system activation induced by atrial natriuretic peptide. Regul Pept 135: 63–68, 2006. doi:10.1016/j.regpep. 2006.04.002.
9. 9. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28: 89–94, 1981. doi:10.1016/0024-3205(81)90370-2.
10. 10. Doust J, Lehman R, Glasziou P. The role of BNP testing in heart failure. Am Fam Physician 74: 1893–1898, 2006.
11. 11. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 94: 2285–2296, 1996. doi: 10.1161/01.CIR.94.9.2285.
12. 12. Elesgaray R, Caniffi C, Ierace DR, Jaime MF, Fellet A, Arranz C, Costa MA. Signaling cascade that mediates endothelial nitric oxide synthase activation induced by atrial natriuretic peptide. Regul Pept 151: 130–134, 2008. doi:10.1016/j.regpep.2008.05.008.
13. 13. Floras JS. Inhibitory effect of atrial natriuretic factor on sympathetic ganglionic neurotransmission in humans. Am J Physiol Regul Integr Comp Physiol 269: R406–R412, 1995.
14. 14. Flynn TG, de Bold ML, de Bold AJ. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun 117: 859–865, 1983. doi:10.1016/0006-291X(83)91675-3.
15. 15. Francis GS. The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure. Am Heart J 118: 642–648, 1989. doi:10.1016/0002-8703(89)90291-3.
16. 16. Fujisaki H, Ito H, Hirata Y, Tanaka M, Hata M, Lin M, Adachi S, Akimoto H, Marumo F, Hiroe M. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 96: 1059–1065, 1995. doi:10.1172/JCI118092.
17. 17. Goetz KL. Physiology and pathophysiology of atrial peptides. Am J Physiol Endocrinol Metab 254: E1–E15, 1988.
18. 18. Inoue T, Nonoguchi H, Tomita K. Physiological effects of vasopressin and atrial natriuretic peptide in the collecting duct. Cardiovasc Res 51: 470–480, 2001. doi:10.1016/S0008-6363(01)00248-6.
19. 19. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95: 948–954, 2005. doi:10.1016/j.amjcard.2004.12.032.
20. 20. Kambayashi Y, Nakao K, Mukoyama M, Saito Y, Ogawa Y, Shiono S, Inouye K, Yoshida N, Imura H. Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett 259: 341–345, 1990. doi:10.1016/0014-5793(90)80043-I.
21. 21. Kangawa K, Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun 118: 131–139, 1984. doi:10.1016/0006-291X(84)91077-5.
22. 22. Kaplinsky E. Sacubitril/valsartan in heart failure: latest evidence and place in therapy. Ther Adv Chronic Dis 7: 278–290, 2016. doi:10.1177/2040622316665350.
23. 23. Kisch B. Electron microscopy of the atrium of the heart. I. Guinea pig. Exp Med Surg 14: 99–112, 1956.
24. 24. Kurtz A, Della Bruna R, Pfeilschifter J, Taugner R, Bauer C. Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. Proc Natl Acad Sci USA 83: 4769–4773, 1986. doi:10.1073/pnas.83.13.4769.
25. 25. Lanese DM, Yuan BH, Falk SA, Conger JD. Effects of atriopeptin III on isolated rat afferent and efferent arterioles. Am J Physiol Renal Fluid Electrolyte Physiol 261: F1102–F1109, 1991.
26. 26. Lee CS, Tkacs NC. Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN Adv Crit Care 19: 364–385, 2008.10.1097/01.AACN.0000340718.93742.c4.
27. 27. Light DB, Corbin JD, Stanton BA. Dual ion-channel regulation by cyclic GMP and cyclic GMP-dependent protein kinase. Nature 344: 336–339, 1990. doi:10.1038/344336a0.
28. 28. Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA, Lewicki JA. Physiological role of silent receptors of atrial natriuretic factor. Science 238: 675–678, 1987. doi:10.1126/science.2823385.
29. 29. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 34: 886–893, 2013. doi:10.1093/eurheartj/ehs262.
30. 30. Marie JP, Guillemot H, Hatt PY. [Degree of granularity of the atrial cardiocytes. Morphometric study in rats subjected to different types of water and sodium load]. Pathol Biol (Paris) 24: 549–554, 1976.
31. 31. Matsukawa T, Miyamoto T. Angiotensin II-stimulated secretion of arginine vasopressin is inhibited by atrial natriuretic peptide in humans. Am J Physiol Regul Integr Comp Physiol 300: R624–R629, 2011. doi: 10.1152/ajpregu.00324.2010.
32. 32. Mattingly MT, Brandt RR, Heublein DM, Wei CM, Nir A, Burnett JC Jr. Presence of C-type natriuretic peptide in human kidney and urine. Kidney Int 46: 744–747, 1994. doi:10.1038/ki.1994.329.
33. 33. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, Duc P, Westheim A, Omland T, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106: 416–422, 2002. doi:10.1161/01.CIR.0000025242.79963.4C.
34. 34. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87: 1402–1412, 1991. doi: 10.1172/JCI115146.
35. 35. Murakami Y, Shimada T, Inoue S, Shimizu H, Ohta Y, Katoh H, Nakamura K, Ishibashi Y. New insights into the mechanism of the elevation of plasma brain natriuretic polypeptide levels in patients with left ventricular hypertrophy. Can J Cardiol 18: 1294–1300, 2002.
36. 36. Ogawa T, de Bold AJ. The heart as an endocrine organ. Endocr Connect 3: R31–R44, 2014. doi:10.1530/EC-14-0012.
37. 37. Ohishi K, Hishida A, Honda N. Direct vasodilatory action of atrial natriuretic factor on canine glomerular afferent arterioles. Am J Physiol Renal Fluid Electrolyte Physiol 255: F415–F420, 1988.
38. 38. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA 94: 14730–14735, 1997. doi:10.1073/pnas.94.26.14730.
39. 39. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, González-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131: 54–61, 2015. doi:10.1161/CIRCULATIONAHA.114.013748.
40. 40. Pandey KN. Dynamics of internalization and sequestration of guanylyl cyclase/atrial natriuretic peptide receptor-A. Can J Physiol Pharmacol 79: 631–639, 2001. doi:10.1139/y01-035.
41. 41. Pandey KN. Emerging roles of natriuretic peptides and their receptors in pathophysiology of hypertension and cardiovascular regulation. J Am Soc Hypertens 2: 210–226, 2008. doi:10.1016/j.jash.2008.02.001.
42. 42. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 191: 341–366, 2009. doi:10.1007/978-3-540-68964-5_15.
43. 43. Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J 278: 1808–1817, 2011. doi:10.1111/j.1742-4658.2011.08082.x.
44. 44. Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health. Clin Sci (Lond) 108: 23–36, 2005. doi:10.1042/CS20040253.
45. 45. Rasmussen MS, Simonsen JA, Sandgaard NC, Høilund-Carlsen PF, Bie P. Mechanisms of acute natriuresis in normal humans on low sodium diet. J Physiol 546: 591–603, 2003. doi:10.1113/jphysiol.2002.027425.
46. 46. Richards AM, Tonolo G, Montorsi P, Finlayson J, Fraser R, Inglis G, Towrie A, Morton JJ. Low dose infusions of 26- and 28-amino acid human atrial natriuretic peptides in normal man. J Clin Endocrinol Metab 66: 465–472, 1988. doi:10.1210/jcem-66-3-465.
47. 47. Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin BV, Zwiener M, Baba HA, Yanagisawa M, Kuhn M. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 115: 1666–1674, 2005. doi:10.1172/JCI23360.
48. 48. Sagnella GA, Singer DR, Markandu ND, MacGregor GA, Shirley DG, Tremblay J, Hamet P. Atrial natriuretic peptide–cyclic GMP coupling and urinary sodium excretion during acute volume expansion in man. Can J Physiol Pharmacol 68: 535–538, 1990. doi:10.1139/y90-077.
49. 49. Semenov AG, Katrukha AG. Analytical issues with natriuretic peptides – has this been overly simplified? EJIFCC 27: 189–207, 2016.
50. 50. Sharma GD, Nguyen HT, Antonov AS, Gerrity RG, von Geldern T, Pandey KN. Expression of atrial natriuretic peptide receptor-A antagonizes the mitogen-activated protein kinases (Erk2 and P38MAPK) in cultured human vascular smooth muscle cells. Mol Cell Biochem 233: 165–173, 2002. doi:10.1023/A:1015882302796.
51. 51. Somanna NK, Yariswamy M, Garagliano JM, Siebenlist U, Mummidi S, Valente AJ, Chandrasekar B. Aldosterone-induced cardiomyocyte growth, and fibroblast migration and proliferation are mediated by TRAF3IP2. Cell Signal 27: 1928–1938, 2015. doi:10.1016/j.cellsig.2015.07.001.
52. 52. Stingo AJ, Clavell AL, Heublein DM, Wei CM, Pittelkow MR, Burnett JC Jr. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol Heart Circ Physiol 263: H1318–H1321, 1992.
53. 53. Stokes NR, Dietz BW, Liang JJ. Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea. Open Access Emerg Med 8: 35–45, 2016. doi:10.2147/OAEM.S71446.
54. 54. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 332: 78–81, 1988. doi:10.1038/332078a0.
55. 55. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 168: 863–870, 1990. doi:10.1016/0006-291X(90)92401-K.
56. 56. Suga S, Nakao K, Itoh H, Komatsu Y, Ogawa Y, Hama N, Imura H. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of “vascular natriuretic peptide system”. J Clin Invest 90: 1145–1149, 1992. doi:10.1172/JCI115933.
57. 57. Theilig F, Wu Q. ANP-induced signaling cascade and its implications in renal pathophysiology. Am J Physiol Renal Physiol 308: F1047–F1055, 2015. doi:10.1152/ajprenal.00164.2014.
58. 58. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 6: 261–268, 2004. doi: 10.1016/j.ejheart.2004.01.004.
59. 59. van Kimmenade RR, Januzzi JL Jr. The evolution of the natriuretic peptides–Current applications in human and animal medicine. J Vet Cardiol 11, Suppl 1: S9–S21, 2009. doi:10.1016/j.jvc.2009.01.001.
60. 60. Veldkamp PJ, Carmines PK, Inscho EW, Navar LG. Direct evaluation of the microvascular actions of ANP in juxtamedullary nephrons. Am J Physiol Renal Fluid Electrolyte Physiol 254: F440–F444, 1988.
61. 61. Vellaichamy E, Kaur K, Pandey KN. Enhanced activation of proinflammatory cytokines in mice lacking natriuretic peptide receptor-A. Peptides 28: 893–899, 2007. doi:10.1016/j.peptides.2006.12.009.
62. 62. Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) 130: 57–77, 2015. doi:10.1042/CS20150469.
63. 63. Wijeyaratne CN, Moult PJ. The effect of alpha human atrial natriuretic peptide on plasma volume and vascular permeability in normotensive subjects. J Clin Endocrinol Metab 76: 343–346, 1993. doi:10.1210/jcem.76.2.8432776.
64. 64. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62: e147–e239, 2013. doi:10.1016/j.jacc.2013.05.019.